The present disclosure provides complexes and compositions comprising particles, microparticles or nanoparticles, for delivery of payloads into a cell or across a polarized epithelial cell. The compositions can comprise a payload in a pill or tablet for delivery of the payload into or across a polarized epithelial cell.

The present invention relates to use of an enzyme that cleaves both alpha- and beta-1,4-glycosidic bonds and, more particularly, the present invention provides α-L-fucosidase which has α-1,4-glucosidase and β-1,4-galactosidase activities and thus is capable of producing glucose and/or galactose, which are monosaccharides, from non-fucosylated saccharides. The enzyme has transglycosylation activity and thus produces maltooligosaccharides having a higher degree of polymerization than maltooligosaccharides used as a substrate, thereby being applicable to the development of high-value-added new materials in the food industry.

The present invention relates to a primer set for detecting food poisoning bacteria by using a next-generation sequencing method and a method for detecting food poisoning bacteria by using the primer set. Specifically, with the primer set in accordance with the present invention, 16 kinds of food poisoning bacteria can be detected at one time, for a shorter time, and with high accuracy, and the primer set can be useful for simultaneous detection of food poisoning bacteria.

The present invention relates to a plasmid-based CTX phage replication system and Vibrio cholerae strain that can be infected by CTX phage and can be used for cholera toxin production. More particularly, the present invention provides a Vibrio cholera variant strain, which expresses a toxT protein in which tyrosine at position 139 is substituted by phenylalanine through the point mutation of a toxT gene using a plasmid-based CTX phage replication system, and is used as a receptor strain which can improve CTX phage infection efficiency and allows a plurality of CTX prophages to simultaneously infect the strain and to be inserted into the chromosome thereof, which the consequent provision of the effect of increasing the production yield of a cholera toxin.

The invention provides engineered Vibrio sp. organisms that comprise a genetic modification to either or both of the lpxL and/or lpxM genes. The organisms score substantially lower in an in vitro endotoxin assay versus the unmodified or wild type organism. The organisms preserve substantially the growth rate of the corresponding unmodified organisms. The organisms can also have an exogenous nucleic acid cloned in the organism, or an exogenous nucleic acid encoding a protein, polypeptide, or peptide expressed by the organism, and optionally secreted from the organism.

The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A.sup.386 (Cholix.sup.386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. The systems and methods described herein provide for: the ability to deliver macromolecule doses without injections; the ability to deliver cargo such as siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes.

The invention provides engineered Vibrio sp. organisms that comprise a genetic modification to either or both of the lpxL and/or lpxM genes. The organisms score substantially lower in an in vitro endotoxin assay versus the unmodified or wild type organism. The organisms preserve substantially the growth rate of the corresponding unmodified organisms. The organisms can also have an exogenous nucleic acid cloned in the organism, or an exogenous nucleic acid encoding a protein, polypeptide, or peptide expressed by the organism, and optionally secreted from the organism.

The present invention relates to a novel microorganism capable of metabolizing various carbon sources at high rates. A novel microorganism according to the present invention was observed to grow at a very high rate in a minimal medium/nutrient medium, etc., compared to microorganisms such as Escherichia coli, and shows resistance at a high initial sugar/salt concentrations as well as being able to produce lycopene and 2,3-butanediol through genetic manipulation. Therefore, the novel microorganism can be used in various production fields of high value-added compounds using microorganisms.

Provided herein are genetically engineered Vibrio cholerae bacterial strains, compositions including the bacterial strains, and methods of using the same for the prevention of Vibrio cholerae infection in a subject.

The inventive technology may include novel systems for regulation of the expression of bacterial genes through the introduction of antisense RNA (asRNA) that may disrupt expression of targeted pathogenic genes and/or their products (mRNA, proteins). In some embodiments, the inventive technology may include novel genetically engineered donor bacterial strains that are configured to efficiently and continuously deliver asRNA polynucleotides to a recipient pathogen and downregulate expression or one or more essential genes.